MRCT will humanize two mAbs that reportedly promote clearance of beta amyloid from the brain.

Medical Research Council Technology (MRCT) is collaborating with Intellect Neurosciences to humanize Intellect’s beta-amyloid specific mAbs for the treatment of Alzheimer’s disease. The antibodies are intended as a form of passive immunization to promote clearance of beta-amyloid from the brain.

“The humanization step marks an important milestone in the development of our antibodies,” remarks Daniel Chain, CEO and chairman of Intellect. “Our monoclonal antibodies incorporate a unique safety feature that is needed to avoid the danger of interference with the important physiological functions of other related proteins.”

Under the terms of the agreement, Intellect will pay MRCT milestone payments related to the development and commercialization of the humanized antibodies and a royalty based on sales of the resulting drug products. Intellect is the holder of patents in Japan and other countries related to antibodies and methods of treatment for Alzheimer’s disease.

Previous articleBioServe and Phenomenome Provide Colorectal Cancer Diagnostic Technology
Next articleBayer and Nektar Partner to Fight Gram-Negative Pneumonias in $175M Alliance